Once-Monthly Semaglutide Depot Begins Phase 1/2a Human Trial

What is the once-monthly semaglutide depot trial?

Mapi Pharma Ltd. has registered a Phase 1/2a study of what the sponsor calls Semaglutide Depot, a long-acting formulation of semaglutide designed for administration once every four weeks. The ClinicalTrials.gov record, identifier NCT07563699, was posted with a 20 August 2026 date and lists the study as recruiting, with a planned enrollment of 24 adults who have type 2 diabetes.

The registry describes a dose-escalation design evaluating safety, tolerability, pharmacokinetics and efficacy. Pharmacokinetics means the measurement of how a drug is absorbed, distributed and cleared over time — in a depot study, that is effectively the whole point, because the question is whether a single administration can maintain useful drug levels across four weeks rather than one.

In the sponsor's own framing on the registry page, semaglutide is already an approved and well-established therapy for type 2 diabetes, and the depot is intended to reduce treatment burden and improve adherence in support of sustained glycemic control. That is a company description of an unapproved formulation, not a finding: no results from this study exist yet.

What a depot formulation actually changes

A depot is a formulation engineered to release its active ingredient slowly from the injection site over an extended period, rather than being absorbed over hours or days. Long-acting depots are familiar in other therapeutic areas — contraception, antipsychotics, opioid dependence treatment — where the clinical value of fewer administrations is well established. Applying the approach to a GLP-1 receptor agonist is a newer proposition.

Semaglutide, the molecule marketed by Novo Nordisk as Ozempic, Wegovy and Rybelsus, is already unusually long-lived for a peptide. Its weekly injectable form exists because the molecule was modified to resist rapid breakdown and to bind to albumin in the blood, which slows clearance. A four-week interval would require going considerably further, either through the delivery vehicle or through the depot's release kinetics.

The trade-off with any depot is control. When a formulation is designed to keep releasing drug for a month, the amount already administered cannot be pulled back if a person tolerates it poorly. Early-phase studies with small cohorts and staged escalation are how developers probe that boundary before committing to larger trials.

For people already on an approved weekly product, the semaglutide dosage calculator remains the tool that matches the interval their provider actually prescribed.

The Lyon probiotic tolerability study notes that gastrointestinal adverse events with GLP-1 receptor agonists are dose-dependent and often decline over time. the Lyon probiotic tolerability study.

Why once-monthly dosing matters for adherence

Adherence is the practical reason companies pursue longer intervals. Real-world discontinuation of GLP-1 therapies is high, and the reasons are a mix of cost, supply, gastrointestinal side effects and the ordinary friction of a recurring injection schedule. A formulation requiring twelve or thirteen administrations a year instead of fifty-two removes one of those frictions, though not the others.

Whether it removes enough of them is an open question this trial cannot answer. A 24-person Phase 1/2a study establishes whether the formulation is tolerable and whether its blood concentration profile matches the design intent. Demonstrating that people actually stay on a monthly product longer than a weekly one requires much larger studies conducted over much longer periods, in ordinary clinical settings rather than trial sites.

The sponsor's stated rationale for a four-week formulation is reduced treatment burden, which is the clinical framing of what adherence tracking measures in practice.

How big a signal is a 24-person Phase 1/2a study?

Modest, and deliberately so. Phase 1 exists to characterise safety and drug handling in a small group; the 2a designation signals an early look at whether the drug does anything measurable in patients rather than healthy volunteers. Twenty-four participants is enough to detect common adverse effects and to build a pharmacokinetic curve. It is not enough to detect uncommon harms or to quantify glycemic or weight outcomes with any precision.

The relevant historical caution is that most compounds entering Phase 1 never reach approval, and formulation projects fail for reasons that have nothing to do with the underlying molecule — the release profile drifts, injection-site reactions prove unacceptable, or manufacturing at scale turns out to be impractical. A registry posting is the start of a process that typically runs for years.

The Lyon probiotic study's focus on gastrointestinal tolerability is a reminder of why consistent side-effect logging against administration dates is more informative than recalling a bad week after the fact.

Other GLP-1 registry activity the same week

The depot posting was one of several GLP-1 entries updated on ClinicalTrials.gov in mid-August. Arrowhead Pharmaceuticals is running a first-in-human Phase 1/2a study of ARO-INHBE, listed under NCT06700538 with a planned enrollment of 180 adults with obesity, including later parts that evaluate the candidate both as monotherapy and in combination with tirzepatide. That combination design reflects a broader pipeline shift toward layering new mechanisms on top of an incretin backbone rather than replacing it.

Elsewhere, Hospices Civils de Lyon registered a 50-participant study, NCT07213323, testing whether a probiotic intervention affects digestive tolerability in people with obesity starting GLP-1 receptor agonist therapy. The registry entry notes that gastrointestinal adverse events with this drug class are dose-dependent and commonly ease over time, and that in Phase 3 work such events led to dose reduction or temporary interruption in a minority of participants.

Novo Nordisk also marked as completed a small Phase 3 mechanistic study, NCT05891496, examining semaglutide's effects on the immune system and other biological processes in people with Alzheimer's disease. With 23 participants and a roughly 77-week design, it is a substudy rather than an outcomes trial, and no results were attached to the registry update.

According to the ClinicalTrials.gov registry entry, the Phase 1/2a dose-escalation study will assess safety, tolerability, pharmacokinetics and efficacy of the depot in 24 adults with type 2 diabetes.

What is still unresolved

Nothing about the depot's performance is public. The registry entry states design and intent; it does not report a single measurement. There is no comparison arm against weekly injectable semaglutide, no timeline for completion given in the excerpt available, and no indication of whether the sponsor intends to pursue the formulation in obesity as well as type 2 diabetes.

The other unknown is regulatory. A new formulation of an approved molecule follows its own approval pathway and must demonstrate its own safety and pharmacokinetic case. Even a clean early-phase result would leave years of development ahead, and the market context — patents, supply, and the compounding landscape around semaglutide — will look different by the time any of it resolves.

Arrowhead's first-in-human ARO-INHBE listing describes a 180-participant Phase 1/2a study with later parts evaluating the candidate alongside tirzepatide.